Security key
31189P102
FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE)
CUSIP: 31189P102
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 122,342,805
- Total 13F shares
- 80,446,666
- Share change
- +1,160,185
- Total reported value
- $101,355,707
- Put/Call ratio
- 38%
- Price per share
- $1.26
- Number of holders
- 138
- Value change
- +$1,878,808
- Number of buys
- 63
- Number of sells
- 53
Report period
Q3 2025
Institutions
138
Top holders
10
FATE full security history
Newer quarter: Q4 2025
Previous quarter: Q2 2025
FATE THERAPEUTICS INC SEC filings
FATE THERAPEUTICS INC company facts
Broader feeds
Reporting periods
Holder history for CUSIP 31189P102
Recent filing periods:
Top shareholders of FATE - FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Redmile Group, LLC |
13F
|
Company |
11%
|
12,872,946
|
$14,417,700 | — | 30 Jun 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
6.9%
from 13D/G
|
10,810,481
|
$12,107,739 | — | 30 Jun 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
7.2%
|
8,766,764
|
$9,818,776 | — | 30 Jun 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
3.7%
|
4,543,867
|
$5,089,131 | — | 30 Jun 2025 | |
| JOHNSON & JOHNSON |
13F
|
Company |
2.8%
|
3,379,064
|
$3,514,227 | — | 30 Jun 2025 | |
| J. Scott Wolchko |
3/4/5
|
President and CEO, Director |
—
mixed-class rows
|
871,248
mixed-class rows
|
$2,987,354 | — | 01 Feb 2024 | |
| Vestal Point Capital, LP |
13F
|
Company |
2.1%
|
2,515,000
|
$2,816,800 | — | 30 Jun 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
13D/G
|
Company · THE GOLDMAN SACHS GROUP, INC. |
2%
from 13D/G
|
2,511,676
|
$2,813,077 | — | 30 Jun 2025 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
2%
|
2,485,018
|
$2,783,220 | — | 30 Jun 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
2%
|
2,459,954
|
$2,754,000 | — | 30 Jun 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
2%
|
2,437,729
|
$2,729,708 | — | 30 Jun 2025 | |
| MORGAN STANLEY |
13F
|
Company |
2%
|
2,433,575
|
$2,725,606 | — | 30 Jun 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2%
|
2,429,167
|
$2,721,072 | — | 30 Jun 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.8%
|
2,229,121
|
$2,496,616 | — | 30 Jun 2025 | |
| CITIGROUP INC |
13F
|
Company |
1.6%
|
1,903,738
|
$2,132,186 | — | 30 Jun 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
1.5%
|
1,867,773
|
$2,091,906 | — | 30 Jun 2025 | |
| Edward J. Dulac III |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
526,479
mixed-class rows
|
$1,948,742 | — | 04 Mar 2024 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.99%
|
1,213,736
|
$1,359,384 | — | 30 Jun 2025 | |
| Jerome Charles Bressi |
3/4/5
|
Chief Regulatory and Quality Officer |
—
mixed-class rows
|
585,203
mixed-class rows
|
$1,202,065 | — | 15 Jan 2025 | |
| UBS Group AG |
13F
|
Company |
0.79%
|
962,672
|
$1,078,193 | — | 30 Jun 2025 | |
| Schonfeld Strategic Advisors LLC |
13D/G
13F
|
Company |
0.82%
|
937,521
|
$1,050,024 | -$7,679,831 | 30 Jun 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.72%
|
879,688
|
$985,251 | — | 30 Jun 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.69%
|
846,233
|
$947,781 | — | 30 Jun 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.69%
|
844,350
|
$945,672 | — | 30 Jun 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.6%
|
733,911
|
$821,980 | — | 30 Jun 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.58%
|
712,650
|
$798,168 | — | 30 Jun 2025 | |
| Monaco Asset Management SAM |
13F
|
Company |
0.55%
|
675,000
|
$756,000 | — | 30 Jun 2025 | |
| Yu-Waye Chu |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
140,676
|
$614,754 | — | 18 Apr 2023 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.4%
|
493,100
|
$552,272 | — | 30 Jun 2025 | |
| Mark Plavsic |
3/4/5
|
Chief Technical Officer |
—
class O/S missing
|
123,705
|
$540,591 | — | 10 Jan 2023 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.38%
|
465,820
|
$521,717 | — | 30 Jun 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.37%
|
453,072
|
$507,441 | — | 30 Jun 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.35%
|
432,328
|
$484,207 | — | 30 Jun 2025 | |
| Bruce & Co., Inc. |
13F
|
Company |
0.35%
|
429,188
|
$480,691 | — | 30 Jun 2025 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.28%
|
339,714
|
$380,479 | — | 30 Jun 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.28%
|
336,872
|
$377,297 | — | 30 Jun 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.24%
|
290,652
|
$325,530 | — | 30 Jun 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.24%
|
289,232
|
$323,940 | — | 30 Jun 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.23%
|
287,412
|
$321,901 | — | 30 Jun 2025 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.21%
|
256,722
|
$288,000 | — | 30 Jun 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.21%
|
255,372
|
$286,017 | — | 30 Jun 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.19%
|
228,405
|
$255,814 | — | 30 Jun 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.18%
|
214,463
|
$240,199 | — | 30 Jun 2025 | |
| Assenagon Asset Management S.A. |
13F
|
Company |
0.17%
|
212,342
|
$237,823 | — | 30 Jun 2025 | |
| Neelufar Mozaffarian |
3/4/5
|
Director |
—
class O/S missing
|
55,000
|
$218,400 | — | 29 May 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.15%
|
187,700
|
$210,224 | — | 30 Jun 2025 | |
| Powl Brian T. |
3/4/5
|
Chief Commercial Officer |
—
class O/S missing
|
41,146
|
$179,808 | — | 05 Jul 2023 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.13%
|
155,858
|
$174,550 | — | 30 Jun 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.12%
|
149,952
|
$168,000 | — | 30 Jun 2025 | |
| Yuan Xu |
3/4/5
|
Director |
—
mixed-class rows
|
63,669
mixed-class rows
|
$145,870 | — | 29 May 2025 |
Institutional Holders of FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) as of Q3 2025
As of 30 Sep 2025,
FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) was held by
138 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
80,446,666 shares.
The largest 10 holders included
Redmile Group, LLC, BlackRock, Inc., VANGUARD GROUP INC, Wilshire Advisors LLC, JOHNSON & JOHNSON, ACADIAN ASSET MANAGEMENT LLC, GEODE CAPITAL MANAGEMENT, LLC, Vestal Point Capital, LP, STATE STREET CORP, and DIMENSIONAL FUND ADVISORS LP.
This page lists
139
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
136
Q3 2025 holders
138
Holder diff
2
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.